DOJ drops Abbott Labs case, signaling softer stance on corporate enforcement

The Department of Justice closed its investigation into Abbott Laboratories, marking another example of reduced corporate prosecution. For indie makers watching regulatory trends, this suggests larger enterprises may face fewer compliance pressures—though bootstrapped founders operating at smaller scale typically navigate different legal terrain than pharma manufacturers.